DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Ramin Rafie, MD is an Internist trained in Geriatric, Hospice & Palliative Medicine.Dr. Rafie was born in Iran and grew up in Los Angeles,...
Katherine Hill Ritchie has extensive background running single family offices including a strong emphasis on sourcing alternative investments. Her most recent role involves both...
Amir Baluch, MD, is an investor, serial entrepreneur, and fund manager at BioWise Capital. Dr. Baluch has ten years experience in private equity and...
